DK2692728T3 - UNKNOWN FURANONDERIVATE - Google Patents

UNKNOWN FURANONDERIVATE Download PDF

Info

Publication number
DK2692728T3
DK2692728T3 DK12763979.7T DK12763979T DK2692728T3 DK 2692728 T3 DK2692728 T3 DK 2692728T3 DK 12763979 T DK12763979 T DK 12763979T DK 2692728 T3 DK2692728 T3 DK 2692728T3
Authority
DK
Denmark
Prior art keywords
mmol
eller
oxo
dihydrofuran
carboxylate
Prior art date
Application number
DK12763979.7T
Other languages
Danish (da)
English (en)
Inventor
Takayuki Irie
Ayako Sawa
Masaaki Sawa
Tokiko ASAMI
Yoko Funakoshi
Chika Tanaka
Original Assignee
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc
Application granted granted Critical
Publication of DK2692728T3 publication Critical patent/DK2692728T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK12763979.7T 2011-03-31 2012-03-30 UNKNOWN FURANONDERIVATE DK2692728T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011080185 2011-03-31
PCT/JP2012/058636 WO2012133802A1 (ja) 2011-03-31 2012-03-30 新規フラノン誘導体

Publications (1)

Publication Number Publication Date
DK2692728T3 true DK2692728T3 (en) 2018-10-08

Family

ID=46931496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12763979.7T DK2692728T3 (en) 2011-03-31 2012-03-30 UNKNOWN FURANONDERIVATE

Country Status (12)

Country Link
US (3) USRE46815E1 (enExample)
EP (1) EP2692728B1 (enExample)
JP (3) JP5659356B2 (enExample)
KR (1) KR101964479B1 (enExample)
CN (1) CN103459388B (enExample)
AU (3) AU2012233246B2 (enExample)
BR (1) BR112013024957A2 (enExample)
CA (1) CA2830148C (enExample)
DK (1) DK2692728T3 (enExample)
ES (1) ES2687450T3 (enExample)
MX (1) MX344474B (enExample)
WO (1) WO2012133802A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46815E1 (en) 2011-03-31 2018-05-01 Carna Biosciences, Inc. Furanone derivative
WO2015115355A1 (ja) * 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 抗がん剤組成物
CN104744353B (zh) * 2015-03-31 2017-11-24 山东友帮生化科技有限公司 2‑氨基‑3‑碘‑5‑氯吡啶的合成方法
US20200055848A1 (en) * 2016-11-04 2020-02-20 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
US20210393620A1 (en) * 2018-09-24 2021-12-23 Sierra Oncology, Inc. Methods of Treatment of Cancer Comprising CDC7 Inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
DE60320560T2 (de) 2002-07-17 2008-12-11 Pfizer Italia S.R.L. Heterobicyclische pyrazolderivate als kinaseinhibitoren
US20050143371A1 (en) 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
BRPI0413438A (pt) 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PL1805175T3 (pl) * 2004-10-14 2008-08-29 Hoffmann La Roche Nowe azaindolotiazolinony jako środki przeciwrakowe
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA94097C2 (ru) 2006-03-27 2011-04-11 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
WO2008109443A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2009155052A1 (en) 2008-05-28 2009-12-23 Wyeth 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010030727A1 (en) * 2008-09-10 2010-03-18 Wyeth Llc 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2011008915A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
KR20140009106A (ko) 2010-06-29 2014-01-22 에스비아이 바이오테크 가부시키가이샤 아자인돌 유도체
USRE46815E1 (en) * 2011-03-31 2018-05-01 Carna Biosciences, Inc. Furanone derivative
WO2015115355A1 (ja) 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 抗がん剤組成物

Also Published As

Publication number Publication date
WO2012133802A1 (ja) 2012-10-04
AU2017203986A1 (en) 2017-07-06
US8742113B2 (en) 2014-06-03
BR112013024957A2 (pt) 2016-12-20
CA2830148A1 (en) 2012-10-04
AU2012233246B2 (en) 2017-03-30
MX344474B (es) 2016-12-16
JP6256927B2 (ja) 2018-01-10
AU2012233246A1 (en) 2013-10-10
JP5891576B2 (ja) 2016-03-23
KR101964479B1 (ko) 2019-04-01
JP2015042663A (ja) 2015-03-05
USRE48140E1 (en) 2020-08-04
AU2017203986B2 (en) 2019-02-28
EP2692728A1 (en) 2014-02-05
USRE46815E1 (en) 2018-05-01
JPWO2012133802A1 (ja) 2014-07-28
EP2692728B1 (en) 2018-07-04
US20140018533A1 (en) 2014-01-16
CA2830148C (en) 2020-07-28
KR20140056164A (ko) 2014-05-09
JP2016084363A (ja) 2016-05-19
CN103459388A (zh) 2013-12-18
CN103459388B (zh) 2015-11-25
ES2687450T3 (es) 2018-10-25
JP5659356B2 (ja) 2015-01-28
AU2019203483A1 (en) 2019-06-06
EP2692728A4 (en) 2014-08-20
MX2013010962A (es) 2014-04-25

Similar Documents

Publication Publication Date Title
RU2503664C2 (ru) Производное ацилтиомочевины или его соль, и его применение
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
ES2812626T3 (es) Inhibidores de la desmetilasa 1 específica de lisina
JP6256927B2 (ja) 新規フラノン誘導体
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
WO2012171337A1 (en) Therapeutically active compositions and their methods of use
CN109641909B (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
WO2009001021A1 (en) Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
CN118176195A (zh) 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
HK40002867A (en) Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof